

		<b>Median age (IQR - in years)</b>	<b>Sex (Female)</b>
<b>CyTOF</b>	Vi-TT	31.2 (22.6 - 50.1)	11/19 (58%)
	Vi-PS	29.2 (22.2 - 35.6)	9/20 (45%)
<b>ELISpot</b>	Vi-TT	25.5 (23.0 - 37.8)	19/41 (46%)
	Vi-PS	30.5 (22.9 - 44.4)	13/37 (35%)

### **Supplementary Data 1 – Participant characteristics**

Summary statistics are provided based on participants with baseline CyTOF or any ELISpot data. Exact age of participant at D0 was used for calculations.

Vi-TT – Vi Tetanus Toxoid Conjugate Vaccine, Vi-PS – Vi polysaccharide vaccine, IQR – interquartile range, CyTOF – cytometry time of flight, ELISpot – Enzyme-linked immunosorbent spot